Fundraising Fox
Scynexis
NASDAQ: SCYXDurham, US · 4 known investors
Find your way into Scynexis
Sign up to see every warm intro you have to Scynexis
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Scynexis team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
SCYNEXIS is a biopharmaceutical company focused on developing drug therapies for severe rare diseases, including anti-infective and antifungal treatments. The company serves patients in areas of unmet medical need within the pharmaceutical industry.
Founders & leadership
Board
Investors · 4
How we know: Decheng Capital's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Foresite Capital's portfolio page · the S-1 prospectus · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$5.7M disclosed across 1 round · 2011
▶$5.7MraisedFeb 2012 · 11 investors · PharmaceuticalsRule 506(b)
- Yves J. RibeillExecutive Officer, Director
- Horace D. NalleDirector
- Pamela J. KirbyDirector
- Laurent ArthaudDirector
- Mounia ChaouiDirector
- Patrick LangloisDirector
- Jean-Yves NothiasDirector
- Charles F. Osborne, Jr.Executive Officer
- Brian SchwabExecutive Officer
- Ed PenhoetDirector
- Ann F. HanhamDirector
- Offering amount
- $15M
- Amount sold
- $5.7M
- First sale
- Dec 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
2 people who came through Scynexis went on to found or lead other companies.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $224K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $224.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Scynexis do?
- SCYNEXIS is a biopharmaceutical company focused on developing drug therapies for severe rare diseases, including anti-infective and antifungal treatments. The company serves patients in areas of unmet medical need within the pharmaceutical industry.
- Who founded Scynexis?
- Scynexis was founded by Yves J. Ribeill.
- Who are Scynexis's investors?
- Scynexis's investors include Decheng Capital, Foresite Capital, Deerfield Management Company, RA Capital.
- How much funding has Scynexis raised?
- Scynexis has disclosed $5.7M raised across 1 round.
- Where is Scynexis headquartered?
- Scynexis is headquartered in Durham, US.